Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Assets Average (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Assets Average for 5 consecutive years, with $178.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 263.56% year-over-year to $178.1 million, compared with a TTM value of $178.1 million through Dec 2025, up 263.56%, and an annual FY2025 reading of $108.5 million, up 69.35% over the prior year.
  • Assets Average was $178.1 million for Q4 2025 at SAB Biotherapeutics, up from $106.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $178.1 million in Q4 2025 and bottomed at $31.9 million in Q3 2023.
  • Average Assets Average over 5 years is $72.6 million, with a median of $60.9 million recorded in 2022.
  • The sharpest move saw Assets Average crashed 52.18% in 2022, then soared 263.56% in 2025.
  • Year by year, Assets Average stood at $99.0 million in 2021, then plummeted by 47.79% to $51.7 million in 2022, then grew by 8.57% to $56.1 million in 2023, then dropped by 12.72% to $49.0 million in 2024, then skyrocketed by 263.56% to $178.1 million in 2025.
  • Business Quant data shows Assets Average for SABS at $178.1 million in Q4 2025, $106.8 million in Q3 2025, and $34.1 million in Q2 2025.